A novel abiraterone acetate oral suspension for patients with metastatic prostate cancer: An open-label, phase 3, randomized trial

被引：0
|
作者：
Martinez, Imanol
Kernan, Kenneth
Piasecki, Piotr
Hamilton, Joelle P.
Goh, Chee
Arkosy, Peter
Needleman, Sarah
Ratta, Raffaele
Tadayon, Mehrnaz
Watissee, Marie
Duus, Elizabeth
Dreicer, Robert
机构：
[1] Jimenez Diaz Fdn Univ Hosp, Madrid, Spain
[2] Michigan Inst Urol, Troy, MI USA
[3] In Vivo Sp ZOO, Bydgoszcz, Poland
[4] Urol Ctr Alabama, Homewood, AL USA
[5] Royal Surrey Cty Hosp, Guildford, Surrey, England
[6] Debrecen Oncol, Debrecen, Hungary
[7] Royal Free Hosp, London, England
[8] Hop Foch, Suresnes, France
[9] TMC Pharma, Harley Wintney, England
[10] WStats, London, England
[11] Tavanta Therapeut, King Of Prussia, PA USA
[12] Univ Virginia, Ctr Comprehens Canc, Charlottesville, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5052
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer
    Hickish, Tamas
    Cassidy, Jim
    Propper, David
    Chau, Ian
    Falk, Stephen
    Ford, Hugo
    Iveson, Tim
    Braun, Michael
    Potter, Vanessa
    Macpherson, Iain R.
    Finnigan, Helen
    Lee, Chooi
    Jones, Hilary
    Harrison, Mark
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3136 - 3144
  • [22] An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer
    Pezaro, Carmel
    Rosenthal, Mark A.
    Gurney, Howard
    Davis, Ian D.
    Underhill, Craig
    Boyer, Michael J.
    Kotasek, Dusan
    Solomon, Benjamin
    Toner, Guy C.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (04): : 338 - 341
  • [23] TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
    Chiara Cremolini
    Federica Marmorino
    Fotios Loupakis
    Gianluca Masi
    Carlotta Antoniotti
    Lisa Salvatore
    Marta Schirripa
    Luca Boni
    Vittorina Zagonel
    Sara Lonardi
    Giuseppe Aprile
    Emiliano Tamburini
    Vincenzo Ricci
    Monica Ronzoni
    Filippo Pietrantonio
    Chiara Valsuani
    Gianluca Tomasello
    Alessandro Passardi
    Giacomo Allegrini
    Samantha Di Donato
    Daniele Santini
    Alfredo Falcone
    BMC Cancer, 17
  • [24] TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
    Cremolini, Chiara
    Marmorino, Federica
    Loupakis, Fotios
    Masi, Gianluca
    Antoniotti, Carlotta
    Salvatore, Lisa
    Schirripa, Marta
    Boni, Luca
    Zagonel, Vittorina
    Lonardi, Sara
    Aprile, Giuseppe
    Tamburini, Emiliano
    Ricci, Vincenzo
    Ronzoni, Monica
    Pietrantonio, Filippo
    Valsuani, Chiara
    Tomasello, Gianluca
    Passardi, Alessandro
    Allegrini, Giacomo
    Di Donato, Samantha
    Santini, Daniele
    Falcone, Alfredo
    BMC CANCER, 2017, 17
  • [25] An Open-Label Trial of SMK Treatment of Advanced Metastatic Cancer
    Hoffman, S.
    Bruckner, H.
    Stega, D.
    Demurjian, A.
    Gurell, D.
    Mull, R.
    Demurjian, M.
    Del Priore, G.
    Malanowska-Stega, J.
    18TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI), 2014, : 473 - 480
  • [26] Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.
    Mateo, Joaquin
    Fizazi, Karim
    Pezaro, Carmel Jo
    Loriot, Yohann
    Mehra, Niven
    Albiges, Laurence
    Bianchini, Diletta
    Varga, Andrea
    Ryan, Charles J.
    Petrylak, Daniel Peter
    Shen, Liji
    Zhang, Jenny
    Attard, Gerhardt
    De Bono, Johann Sebastian
    Massard, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [27] CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
    de Wit, R.
    Kramer, G.
    Eymard, J-C.
    de Bono, J. S.
    Sternberg, C. N.
    Fizazi, K.
    Tombal, B.
    Wuelfing, C.
    Bamias, A.
    Carles, J.
    Iacovelli, R.
    Melichar, B.
    Sverrisdottir, A.
    Theodore, C.
    Feyerabend, S.
    Helissey, C.
    Picard, P.
    Ozatilgan, A.
    Geffriaud-Ricouard, C.
    Castellano, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 882 - +
  • [28] A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.
    Abu-Khalaf, Maysa M.
    Mayer, Ingrid A.
    Tankersley, Chris
    Moy, Jadine
    Allen, Andrew R.
    Vogel, Charles L.
    Holmes, Frankie Ann
    Nanda, Rita
    Miller, Kathy
    Patel, Ravindranath
    Pusztai, Lajos
    Arteaga, Carlos L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
    Fizazi, Karim
    Kramer, Gero
    Eymard, Jean-Christophe
    Sternberg, Cora N.
    de Bono, Johann
    Castellano, Daniel
    Tombal, Bertrand
    Whuelfing, Christian
    Liontos, Michael
    Carles, Joan
    Iacovelli, Roberto
    Melichar, Bohuslav
    Sverrisdottir, Asgerdur
    Theodore, Christine
    Feyerabend, Susan
    Helissey, Carole
    Oudard, Stephan
    Facchini, Gaetano
    Poole, Elizabeth M.
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    Bensfia, Samira
    de Wit, Ronald
    LANCET ONCOLOGY, 2020, 21 (11): : 1513 - 1525
  • [30] First-line FOLFOX-4 ± cetuximab in patients with RAS wildtype metastatic colorectal cancer: The open-label, randomized, phase 3 TAILOR trial
    Qin, S.
    Xu, J.
    Wang, L.
    Cheng, Y.
    Liu, T.
    Chen, J.
    Liu, J.
    Li, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345